Fatty acid synthase (FASN) signalome: A molecular guide for precision oncology
The initial excitement generated more than two decades ago by the discovery of drugs targeting fatty acid synthase (FASN)‐catalyzed de novo lipogenesis for cancer therapy was short‐lived. However, the advent of the first clinical‐grade FASN inhibitor (TVB‐2640; denifanstat), which is currently being...
Main Authors: | Javier A. Menendez, Elisabet Cuyàs, Jose Antonio Encinar, Travis Vander Steen, Sara Verdura, Àngela Llop‐Hernández, Júlia López, Eila Serrano‐Hervás, Sílvia Osuna, Begoña Martin‐Castillo, Ruth Lupu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-03-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.13582 |
Similar Items
-
Adhesive analysis of painted coatings
by: Deividas Grinius, et al.
Published: (2010-08-01) -
Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer
by: Javier A. Menendez, et al.
Published: (2020-10-01) -
Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
by: Javier A. Menendez, et al.
Published: (2021-03-01) -
Metformin: Targeting the Metabolo-Epigenetic Link in Cancer Biology
by: Elisabet Cuyàs, et al.
Published: (2021-02-01) -
Nutritional Niches of Cancer Therapy-Induced Senescent Cells
by: Àngela Llop-Hernández, et al.
Published: (2022-09-01)